Tacrine
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Tacrine?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Tacrine is a centrally acting acetylcholinesterase inhibitor and indirect cholinergic agonist (parasympathomimetic). It was the first centrally acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex. Tacrine was first synthesised by Adrien Albert at the University of Sydney in 1949. It also acts as a histamine N-methyltransferase inhibitor.[2]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Cognex |
AHFS/Drugs.com | Monograph |
MedlinePlus | a693039 |
Pregnancy category |
|
Routes of administration | Oral, rectal |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 2.4–36% (oral) |
Protein binding | 55% |
Metabolism | Hepatic (CYP1A2) |
Elimination half-life | 2–4 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL |
|
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.721 |
Chemical and physical data | |
Formula | C13H14N2 |
Molar mass | 198.269 g·mol−1 |
3D model (JSmol) | |
Melting point | 183 °C (361 °F) |
Boiling point | 358 °C (676 °F) |
| |
| |
(verify) |
Close